Camille L. Bedrosian — EVP & Chief Medical Officer at Ultragenyx Pharmaceutical

Dr. Camille L. Bedrosian, M.D., has been Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc., January 29, 2018. Dr. Bedrosian served as Chief Medical Officer and Senior Vice President of Alexion Pharmaceuticals, Inc. since May 2008. Dr. Bedrosian has more than 25 years of medical practice, research and drug development experience. Dr. Bedrosian has global responsibility for aspects of clinical research, such as clinical operations, clinical data management, medical affairs and pharmacovigilance. She served as Chief Medical Officer and Vice President of Ariad Pharmaceuticals Inc., from September 2002 to 2008 and since September 2002 respectively. From 1997 to 2002, Dr. Bedrosian was the Senior Director of Oncology, Hematology, and Therapeutic Area and Director for Hemophilia at Genetics Institute, LLC. From 1986 to 1997, she was a Fellow, an Associate, and Assistant Professor of Medicine in the Division of Hematology and Oncology at Duke University Medical Center and the Duke Comprehensive Cancer Center. Dr. Bedrosian is the author of numerous research publications, patents, presentations, and abstracts, and is a member of several professional associations, including the American Association for Cancer Research, American Association for the Advancement of Sciences, American Society of Clinical Oncology and American Society of Hematology. In 2005, she was recipient of the Symbol of Caring Award from the Sarcoma Foundation of America. Dr. Bedrosian received her B.A. degree from Harvard University/Radcliffe College in Chemistry, her M.S. in Biophysics from M.I.T., and her M.D. from Harvard Medical School.